Literature DB >> 33634254

Androgen receptor-reduced sensitivity is associated with increased mortality and poorer glycaemia in men with type 2 diabetes mellitus: a prospective cohort study.

Adrian H Heald1,2, Ghasem Yadegar Far1,3, Mark Livingston4, Helene Fachim1,2, Mark Lunt1, Ram Prakash Narayanan5, Kirk Siddals1, Gabriela Moreno6, Richard Jones1,7, Nagaraj Malipatil1,2, Martin Rutter1,8, Martin Gibson1,2, Rachelle Donn1, Geoff Hackett9, Hugh Jones10,11.   

Abstract

INTRODUCTION: Hypogonadism is associated with poorer glycaemic outcomes/increased all-cause and cardiovascular morbidity/mortality in type 2 diabetes mellitus (T2DM). Increasing CAG repeat number within exon-1 of the androgen receptor (AR) gene is associated with increased AR resistance/insulin resistance.
METHODS: We determined in a long-term 14-year follow-up cohort of 423 T2DM Caucasian men, the association between baseline androgen status/CAG repeat number (by PCR then Sequenom sequencing) and metabolic/cardiovascular outcomes.
RESULTS: Metabolic outcomes: Lower total testosterone was associated with higher BMI (kg/m2) at 14-year-follow-up: regression coefficient -0.30 (95% confidence interval -0.445 to -0.157), P = 0.0001. The range of CAG repeat number was 9-29 repeats. Higher CAG repeat number in exon-1 of the AR gene was associated with higher follow-up HbA1c2016 - each unit increase in CAG repeat-associated with an increment of 0.1% in HbA1C2016 (P = 0.04), independent of baseline testosterone. Cardiovascular outcomes and mortality: At an average of 14-year-follow-up, 55.8% of hypogonadal men had died vs 36.1% of eugonadal men (P = 0.001). There was a 'u' shaped relation between number of CAG repeats and mortality. Twenty-one CAG repeats were associated with an up to nearly 50% lower mortality rate than <21 CAG repeats and >21 CAG repeats - independent of baseline testosterone level.
CONCLUSION: A higher number of CAG repeats at the AR gene associates with higher future HbA1c. There was a 'u' shaped relation between CAG repeat number and mortality rate. Determination of CAG repeat number may become part of assessment of androgen status/its consequences for men with T2DM.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Keywords:  BMI; androgen receptor; cardiovascular; mortality; testosterone; type 2 diabetes

Year:  2020        PMID: 33634254      PMCID: PMC7901820          DOI: 10.1097/XCE.0000000000000230

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol Metab        ISSN: 2574-0954


  30 in total

1.  A critical evaluation of simple methods for the estimation of free testosterone in serum.

Authors:  A Vermeulen; L Verdonck; J M Kaufman
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

2.  The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men.

Authors:  M Zitzmann; J Gromoll; A von Eckardstein; E Nieschlag
Journal:  Diabetologia       Date:  2002-12-20       Impact factor: 10.122

3.  Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes.

Authors:  Vakkat Muraleedharan; Hazel Marsh; Dheeraj Kapoor; Kevin S Channer; T Hugh Jones
Journal:  Eur J Endocrinol       Date:  2013-10-21       Impact factor: 6.664

4.  Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial.

Authors:  Irina Khripun; Sergey Vorobyev; Igor Belousov; Michel Kogan; Michael Zitzmann
Journal:  Aging Male       Date:  2018-09-20       Impact factor: 5.892

Review 5.  Testosterone deficiency: a risk factor for cardiovascular disease?

Authors:  T H Jones
Journal:  Trends Endocrinol Metab       Date:  2010-04-08       Impact factor: 12.015

6.  AR CAG repeat length is not associated with serum gonadal steroids and lipid levels in healthy men.

Authors:  Maria Goutou; Christina Sakka; Nikos Stakias; Ioannis Stefanidis; Georgios N Koukoulis
Journal:  Int J Androl       Date:  2008-07-24

7.  The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study.

Authors:  R D Stanworth; S Akhtar; K S Channer; T H Jones
Journal:  Eur J Endocrinol       Date:  2013-12-21       Impact factor: 6.664

8.  Testosterone concentrations in women and men with NIDDM.

Authors:  B Andersson; P Mårin; L Lissner; A Vermeulen; P Björntorp
Journal:  Diabetes Care       Date:  1994-05       Impact factor: 19.112

9.  State-of-the-art of serum testosterone measurement by isotope dilution-liquid chromatography-tandem mass spectrometry.

Authors:  Linda M Thienpont; Katleen Van Uytfanghe; Stuart Blincko; Carol S Ramsay; Hui Xie; Robert C Doss; Brian G Keevil; Laura J Owen; Alan L Rockwood; Mark M Kushnir; Kelly Y Chun; Donald W Chandler; Helen P Field; Patrick M Sluss
Journal:  Clin Chem       Date:  2008-06-12       Impact factor: 8.327

Review 10.  Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention?

Authors:  Dheeraj Kapoor; T Hugh Jones
Journal:  Drugs Aging       Date:  2008       Impact factor: 4.271

View more
  1 in total

1.  Androgen receptor polymorphism, testosterone levels, and prognosis in patients with acute myocardial infarction.

Authors:  Anne Wang; John Flanagan; Stefan Arver; Anna Norhammar; Per Näsman; Lars Rydén; Linda G Mellbin
Journal:  Eur Heart J Open       Date:  2021-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.